Loading...
XSHE300391
Market cap264mUSD
Dec 27, Last price  
5.51CNY
1D
2.23%
1Q
31.50%
Jan 2017
-62.12%
IPO
32.54%
Name

Changjiang Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHE:300391 chart
P/E
—
P/S
1.61
EPS
—
Div Yield, %
3.21%
Shrs. gr., 5y
8.72%
Rev. gr., 5y
6.33%
Revenues
1.20b
-25.86%
128,131,531177,609,816223,180,306225,272,826255,385,121243,428,659191,250,584234,866,048744,154,806881,022,368725,310,8821,214,503,9602,361,946,4501,615,322,9341,197,562,401
Net income
-606m
17,770,45430,808,33237,133,20735,477,99134,958,54328,718,7065,027,9974,221,13969,716,990101,988,481025,319,98849,104,5240-605,653,315
CFO
-147m
21,348,50027,067,80030,360,68629,341,43821,658,761040,984,292038,957,030137,087,58122,302,17832,805,640230,987,8900-147,425,871
Dividend
May 10, 20190.05 CNY/sh
Earnings
May 21, 2025

Profile

Changjiang Pharmaceutical Group Co., Ltd., together with its subsidiaries, designs, researches, develops, produces, and sells turbochargers in China. It offers turbocharger housing, engine exhaust manifolds, and valve body auto parts, as well as engines. The company also produces and sells solar cell module equipment and photovoltaic modules, as well as engages in the solar energy, lithium batteries, energy storage, and other energy industry businesses. Its products are used in automobiles, construction machinery, agricultural machinery, ship power, generator sets, and other industries. Kangyue Technology Co., Ltd. also exports its products to Americas, Europe, East Asia, and internationally. The company was formerly known as Kangyue Technology Co., Ltd. and changed its name to Changjiang Pharmaceutical Group Co., Ltd. in March 2023. Changjiang Pharmaceutical Group Co., Ltd. was founded in 1963 and is based in Shouguang, China.
URL
http://www.chinakangyue.com/
IPO date
Aug 01, 2014
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,197,562
-25.86%
1,615,323
-31.61%
2,361,946
94.48%
Cost of revenue
1,074,262
1,350,195
1,977,243
Unusual Expense (Income)
NOPBT
123,300
265,128
384,704
NOPBT Margin
10.30%
16.41%
16.29%
Operating Taxes
26,324
27,254
Tax Rate
21.35%
10.28%
NOPAT
96,976
237,875
384,704
Net income
(605,653)
 
49,105
93.94%
Dividends
(62,035)
Dividend yield
2.29%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
205,116
609,007
526,705
Long-term debt
529,794
347,240
352,841
Deferred revenue
650
15,903
23,713
Other long-term liabilities
676
4,643
131,145
Net debt
719,706
936,307
756,274
Cash flow
Cash from operating activities
(147,426)
230,988
CAPEX
(6,791)
Cash from investing activities
64,454
Cash from financing activities
77,733
57,576
199,578
FCF
434,877
46,226
(127,513)
Balance
Cash
15,203
17,475
107,697
Long term investments
1
2,466
15,575
Excess cash
5,174
Stockholders' equity
1,172,536
1,232,643
1,154,044
Invested Capital
1,763,346
2,503,237
2,492,963
ROIC
4.55%
9.52%
15.70%
ROCE
6.96%
10.56%
15.35%
EV
Common stock shares outstanding
350,332
350,336
350,336
Price
7.74
-20.62%
9.75
-35.86%
15.20
23.88%
Market cap
2,711,567
-20.62%
3,415,777
-35.86%
5,325,109
23.88%
EV
4,253,474
5,216,032
6,864,395
EBITDA
170,122
380,411
444,316
EV/EBITDA
25.00
13.71
15.45
Interest
61,493
56,031
37,949
Interest/NOPBT
49.87%
21.13%
9.86%